BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33283516)

  • 41. The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.
    Turgeon N; Blais M; Delabre JF; Asselin C
    J Cell Biochem; 2013 May; 114(5):1203-15. PubMed ID: 23192652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation.
    Healy E; Mucha M; Glancy E; Fitzpatrick DJ; Conway E; Neikes HK; Monger C; Van Mierlo G; Baltissen MP; Koseki Y; Vermeulen M; Koseki H; Bracken AP
    Mol Cell; 2019 Nov; 76(3):437-452.e6. PubMed ID: 31521505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PRC2 mediated H3K27 methylations in cellular identity and cancer.
    Conway E; Healy E; Bracken AP
    Curr Opin Cell Biol; 2015 Dec; 37():42-8. PubMed ID: 26497635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
    O'Meara MM; Simon JA
    Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
    Cyrus S; Burkardt D; Weaver DD; Gibson WT
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
    Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
    Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Going beyond Polycomb: EZH2 functions in prostate cancer.
    Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
    Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
    Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
    Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
    Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting EZH2 as cancer therapy.
    Hanaki S; Shimada M
    J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.
    Miller SA; Damle M; Kim J; Kingston RE
    Development; 2021 Apr; 148(7):. PubMed ID: 33688077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
    Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
    Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role and mechanisms of polycomb repressive complex 2 on the regulation of osteogenic and neurogenic differentiation of stem cells.
    Cao Y; Li L; Fan Z
    Cell Prolif; 2021 May; 54(5):e13032. PubMed ID: 33759287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cryptic RNA-binding by PRC2 components EZH2 and SUZ12.
    Betancur JG; Tomari Y
    RNA Biol; 2015; 12(9):959-65. PubMed ID: 26177152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
    Oh EJ; Kim EK; Yang WI; Yoon SO
    Leuk Lymphoma; 2016 Aug; 57(8):1921-32. PubMed ID: 26757888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
    Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ
    Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2.
    Højfeldt JW; Laugesen A; Willumsen BM; Damhofer H; Hedehus L; Tvardovskiy A; Mohammad F; Jensen ON; Helin K
    Nat Struct Mol Biol; 2018 Mar; 25(3):225-232. PubMed ID: 29483650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
    Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
    Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
    Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
    Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.